BTK and pneumonia: Furthermore, an analysis of the Chinese subgroup in the Phoenix study revealed that, compared to the R-CHOP group, combining the BTK inhibitor ibrutinib with R-CHOP increased the incidence of pneumonia-related adverse reactions from 2.1% to 9.7% (13).